

May 24, 2017

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

Scrip code: 532531

The National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051

Scrip code: STAR

Dear Sirs,

Sub: Press Release

Please find attached press release issued by the Company titled:


“Strides Shasun receives USFDA Approval for Memantine Hydrochloride Tablets”

Thanks & Regards,
For **STRIDES SHASUN LIMITED**



**MANJULA RAMAMURTHY
COMPANY SECRETARY**





Press Release

Wednesday, May 24, 2017

Strides Shasun Limited
(Formerly Strides Arcolab Limited)
Strides House, Bannerghatta Road,
Bangalore – 560076.

Strides Shasun receives USFDA Approval for Memantine Hydrochloride Tablets

Product to be manufactured from the Bangalore facility

Bangalore, May 24, 2017: Strides Shasun Limited today announced that it has received approval from the United States Food & Drug Administration (USFDA) for **Memantine Hydrochloride Tablets USP, 5 mg and 10 mg**.

According to IMS data, the US market for Memantine Hydrochloride Tablets USP, 5 mg and 10 mg is approximately USD 60 Million. The product will be manufactured at the Company's flagship facility at Bangalore and marketed by Strides Pharma Inc in the US Market. The product will be launched immediately.

About Memantine Hydrochloride Tablets

Memantine Hydrochloride Tablets are indicated for the treatment of moderate to severe Alzheimer-type dementia

About Strides Shasun Limited

Strides Shasun, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has four business verticals, viz., Regulated Markets, Emerging Markets, Institutional Business and Active Pharmaceutical Ingredients.

The Company has global manufacturing foot print with 8 manufacturing facilities spread across three continents including 6 US FDA approved facilities and 2 facilities for the emerging markets. The Company has three dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 85 countries. Additional information is available at the Company's website at www.stridesarco.com.



For further information, please contact:

<u>Strides Shasun</u> Badree Komandur, Executive Director +91 80 6784 0747 Vikesh Kumar +91 80 6784 0827 Kannan. N: +91 98450 54745 Sandeep Baid: +91 80 6784 0791	<u>PR Consultancy</u> Fortuna PR K Srinivas Reddy: +91 9000527213 srinivas@fortunapr.com K Priya: +91 9535425418 <u>priya@fortunapr.com</u>
--	--

